Method of reducing MACE in diabetic patients subsequent to stent placement
US-9217042-B2 · Dec 22, 2015 · US
US9533073B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9533073-B1 |
| Application number | US-201514709726-A |
| Country | US |
| Kind code | B1 |
| Filing date | May 12, 2015 |
| Priority date | May 22, 2012 |
| Publication date | Jan 3, 2017 |
| Grant date | Jan 3, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides compositions and methods for making and using microvascular stamps for stimulation and spatial organization of neovessels in tissue.
Opening claim text (preview).
We claim: 1. A method of inducing growth of new blood vessels in a tissue comprising contacting one or more microvascular stamps comprising one or more types of cells encapsulated in a poly(ethylene glycol) (PEGDA) and methacrylic polymer cross-linked hydrogel with the tissue, wherein the cross-linked hydrogel comprises microchannels, wherein the new blood vessels are localized within the lumina of the microchannels, and wherein the one or more microvascular stamps induce growth of new blood vessels in the tissue. 2. The method of claim 1 , wherein the one or more types of cells express one or more fusion proteins comprising a growth factor, proangiogenic factor, or antiangiogenic factor fused to a protein light switch. 3. The method of claim 2 , wherein the one or more microvascular stamps are illuminated with light at a wavelength of about 450 nm to about 500 nm. 4. The method of claim 1 , wherein microscale spacing between the new blood vessels is regulated by microchannel diameter and spacing. 5. The method of claim 1 , wherein the microscale spacing between the new blood vessels is about 100 μm to about 2.5 mm on-center. 6. The method of claim 1 , wherein the one or more types of cells secrete one or more proangiogenic factors, growth factors, or antiangiogenic factors. 7. The method of claim 1 , wherein the microchannels are about 100 μm to about 2.5 mm in diameter and wherein the on-center spacing between the microchannels is about 100 μm to about 2.5 mm. 8. The method of claim 1 , wherein the ratio between the flux of growth factors through a microchannel wall of the one or more microvascular stamps (J m ) is larger than the flux through a bottom of the one or more microvascular stamps with the same cross-sectional area as the microchannel (J r ). 9. The method of claim 1 , wherein the one or more microvascular stamps are about 100 μm to about 5 mm thick. 10. The method of claim 1 , wherein the one or more microvascular stamps have an elastic modulus of about 10 kPa to about 140 kPa. 11. The method of claim 1 , wherein the tissue is in vivo. 12. The method of claim 11 , wherein the tissue has a defect and the one or more microvascular stamps are contacted with the defect.
Animal cells · CPC title
Materials or treatment for tissue regeneration · CPC title
Hydrogels or hydrocolloids · CPC title
for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062) · CPC title
Mixtures of macromolecular compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.